Pharsight

BOEHRINGER INGELHEIM PATENTS FACING OPPOSITIONS

Top patents of BOEHRINGER INGELHEIM facing oppositions at the European Patent Office (EPO)

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP2981255B1 14 Sep, 2022 Therapeutic Uses Of Empagliflozin Apr, 2034 10
EP2981271B1 14 Nov, 2018 Therapeutic Uses Of Empagliflozin Apr, 2034 8
EP2397142B1 27 Jul, 2022 Use Of Dpp Iv Inhibitors May, 2027 5
EP2986304B1 12 Jan, 2022 Pharmaceutical Composition, Methods For Treating And Uses Thereof Apr, 2034 4
EP2285410B1 26 Sep, 2018 Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation Apr, 2029 4
EP2994125B1 01 Aug, 2018 Efficacious Treatment Of Nsclc And Predictive Clinical Marker Of The Responsiveness Of A Tumour To A Treatment May, 2034 4
EP2299987B1 21 Feb, 2018 Capsule Pharmaceutical Dosage Form Comprising A Suspension Formulation Of An Indolinone Derivative Jun, 2029 4
EP2608792B1 11 Oct, 2017 Methods Of Administering An Egfr Inhibitor Aug, 2031 4
EP2313087B2 22 Nov, 2023 Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative Jun, 2029 3
EP2482812B1 11 Jan, 2023 Therapeutic Uses Of Pharmaceutical Compositions Oct, 2030 3
EP3517539B1 14 Dec, 2022 Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes Jul, 2032 3
EP2275132B1 03 Mar, 2021 Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Them Dec, 2026 3
EP3127551B1 29 Jul, 2020 Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In Pigs Dec, 2026 3
EP2956483B1 27 May, 2020 Therapeutic And Diagnostic Target For Cancer Comprising Dll3 Binding Reagents Feb, 2034 3
EP2395983B1 08 Apr, 2020 Pharmaceutical Composition Comprising A Sglt2 Inhibitor, A Dpp-Iv Inhibitor And Optionally A Further Antidiabetic Agent And Uses Thereof Feb, 2030 3
EP2460820B8 19 Jun, 2019 Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions Dec, 2025 3
EP2451445B1 03 Apr, 2019 Process For Drying Of Bibw2992, Of Its Salts And Of Solid Pharmaceutical Formulations Comprising This Active Ingredient Jul, 2030 3
EP1968630B1 24 Jan, 2018 Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions Dec, 2026 3
EP3110449B1 28 Jun, 2023 Medical Use Of A Dpp-4 Inhibitor NA 2
EP3362055B1 18 Jan, 2023 Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy Oct, 2036 2
EP2566469B1 21 Dec, 2022 Combination Therapy May, 2031 2
EP3035958B1 26 Oct, 2022 Porcine Circovirus Type 2 (Pcv2) Subunit Vaccine Aug, 2034 2
EP2849754B1 14 Sep, 2022 A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or Sepsis May, 2033 2
EP2729151B1 31 Mar, 2021 Pharmaceutical Composition, Methods For Treating And Uses Thereof Jul, 2032 2
EP3061454B1 10 Mar, 2021 Parasiticidal Oral Veterinary Compositions Comprising Systemically-Acting Active Agents, Methods And Uses Thereof Jan, 2033 2
EP3320919B1 27 May, 2020 Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions Dec, 2026 2
EP2640371B1 08 Jan, 2020 Vasoprotective And Cardioprotective Antidiabetic Therapy Nov, 2031 2
EP2152341B1 11 Dec, 2019 Atomizer, And Filter May, 2028 2
EP2504002B1 09 Oct, 2019 Treatment Of Genotyped Diabetic Patients With Dpp-Iv Inhibitors Such As Linagliptin Nov, 2030 2
EP2481420B1 20 Feb, 2019 Single Dose Anti-Pcv2 Pig Vaccine Dec, 2027 2
EP2992897B1 04 Jul, 2018 Immunogenic Compositions Comprising Lawsonia Intercellularis Mar, 2026 2
EP3485890B1 10 May, 2023 Treatment Of Metabolic Disorders In Canine Animals NA 1
EP3534939B1 22 Feb, 2023 Vaccine Against Porcine Parvovirus And Porcine Reproductive And Respiratory Syndrome Virus And Methods Of Production Thereof Nov, 2037 1
EP3554536B1 26 Oct, 2022 Recombinant Hvt Vectors Expressing Multiple Antigens Of Avian Pathogens, And Vaccines Comprising Them Dec, 2037 1
EP2785374B2 17 Aug, 2022 Recombinant Gallid Herpesvirus 3 (Mdv Serotype 2) Vectors Expressing Antigens Of Avian Pathogens And Uses Thereof Nov, 2032 1
EP2998315B2 03 Nov, 2021 Newcastle Disease Virus Vectored Avian Vaccines Apr, 2030 1
EP1720663B2 15 Sep, 2021 Atomiser Comprising Coding Means Feb, 2025 1
EP3526229B1 28 Apr, 2021 Process For Preparing Glucopyranosyl-Substituted Benzyl-Benzene Derivatives Oct, 2037 1
EP2819669B1 21 Apr, 2021 Novel Propellant-Gas-Containing Tiotropium Formulation Feb, 2033 1
EP3288561B1 31 Mar, 2021 Methods And Pharmaceutical Compositions Comprising A Sglt2 Inhibitor For Treating Or Improving Erectile Dysfunction Apr, 2036 1
EP3344289B1 29 Jan, 2020 Pestivirus Vaccines For Congenital Tremors Aug, 2036 1
EP3370810B1 18 Dec, 2019 System With Nebulizer And Container Nov, 2036 1
EP2433665B1 07 Aug, 2019 Inhaler And Sieve For An Inhaler Mar, 2029 1
EP2190434B1 17 Apr, 2019 Purin Derivatives For Use In The Treatment Of Fab-Related Diseases Aug, 2028 1
EP2731947B1 16 Jan, 2019 Substituted Quinazolines, The Preparation Thereof And The Use Thereof In Pharmaceutical Compositions Jul, 2032 1
EP2931741B1 25 Jul, 2018 Porcine Parvovirus 5A, Methods Of Use And Vaccine Jan, 2034 1
EP2606142B1 28 Feb, 2018 Method For Inactivating Proteases By Ph Change In A Liquid Obtained From A Cell Culture Aug, 2031 1
EP1940349B1 14 Feb, 2018 Aerosol Formulation For The Inhalation Of Beta Agonists Oct, 2026 1
EP2874653B1 27 Dec, 2017 Method Of Providing Protective Immunity Against Heterologous Leptospira Strains Jul, 2033 1
EP1951227B1 12 Apr, 2017 Use Of Pde Iii Inhibitors Or Calcium Sensitizers For The Treatment Of Asymptomatic (Occult) Heart Failure Nov, 2026 1
EP2460817B1 29 Mar, 2017 Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions Dec, 2025 1
EP1976558B1 15 Mar, 2017 Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In Pigs Dec, 2026 1